Improving vaccines by incorporating immunological coadjuvants

References

• Bramwell VW, Perrie Y. The rational design of vaccines. Drug Discov. Today10(22), 1527–1534 (2005).
   PubMed Web of Science ®Google Scholar
• Ramon G. Sur la toxine et surranatoxine diphtheriques. Ann. Inst. Pasteur38, 1–7 (1924).
   Google Scholar
• Singh M, O’Hagan DT. Recent advances in vaccine adjuvants. Pharm. Res.19(6), 715–728 (2002).
   PubMed Web of Science ®Google Scholar
• WHO. Immunological adjuvants. Technical report series No. 595, Geneva, Switzerland (1976).
   Google Scholar
• Barr TA, Carlring J, Heath AW. Co-stimulatory agonists as immunological adjuvants. Vaccine24(17), 3399–3407 (2006).
   PubMed Web of Science ®Google Scholar
• Ball R. Methods of ensuring vaccine safety. Expert Rev. Vaccines1(2), 161–168 (2002).
   PubMedGoogle Scholar
• Pashine A, Valiante NM, Ulmer JB. Targeting the innate immune response with improved vaccine adjuvants. Nat. Med.11(4 Suppl.), S63–S68 (2005).
   PubMed Web of Science ®Google Scholar
• Ulmer JB, Valley U, Rappuoli R. Vaccine manufacturing: challenges and solutions. Nat. Biotechnol.24(11), 1377–1383 (2006).
   PubMed Web of Science ®Google Scholar
• Petrovsky N, Aguilar JC. Vaccine adjuvants: current state and future trends. Immunol. Cell Biol.82(5), 488–496 (2004).
   PubMed Web of Science ®Google Scholar
• Creagh EM, O’Neill LA. TLRs, NLRs and RLRs: a trinity of pathogen sensors that co-operate in innate immunity. Trends Immunol.27(8), 352–357 (2006).
   PubMed Web of Science ®Google Scholar
• Trinchieri G, Sher A. Cooperation of Toll-like receptor signals in innate immune defence. Nat. Rev. Immunol.7(3), 179–190 (2007).
   PubMed Web of Science ®Google Scholar
• Verstak B, Hertzog P, Mansell A. Toll-like receptor signalling and the clinical benefits that lie within. Inflamm. Res.56(1), 1–10 (2007).
   PubMed Web of Science ®Google Scholar
• Akira S, Uematsu S, Takeuchi O. Pathogen recognition and innate immunity. Cell124(4), 783–801 (2006).
   PubMed Web of Science ®Google Scholar
• Kawai T, Akira S. Pathogen recognition with Toll-like receptors. Curr. Opin. Immunol.17(4), 338–344 (2005).
   PubMed Web of Science ®Google Scholar
• Fritz JH, Ferrero RL, Philpott DJ, Girardin SE. Nod-like proteins in immunity, inflammation and disease. Nat. Immunol.7(12), 1250–1257 (2006).
   PubMed Web of Science ®Google Scholar
• Delbridge LM, O’Riordan MX. Innate recognition of intracellular bacteria. Curr. Opin. Immunol.19(1), 10–16 (2007).
   PubMed Web of Science ®Google Scholar
• Martinon F, Tschopp J. NLRs join TLRs as innate sensors of pathogens. Trends Immunol.26(8), 447–454 (2005).
   PubMed Web of Science ®Google Scholar
• Agostini L, Martinon F, Burns K, McDermott MF, Hawkins PN, Tschopp J. NALP3 forms an IL-1β-processing inflammasome with increased activity in Muckle–Wells autoinflammatory disorder. Immunity20(3), 319–325 (2004).
   PubMed Web of Science ®Google Scholar
• Kawai T, Akira S. Innate immune recognition of viral infection. Nat. Immunol.7(2), 131–137 (2006).
   PubMed Web of Science ®Google Scholar
• Kato H, Takeuchi O, Sato S et al. Differential roles of MDA5 and RIG-I helicases in the recognition of RNA viruses. Nature441(7089), 101–105 (2006).
   PubMed Web of Science ®Google Scholar
• Hornung V, Ellegast J, Kim S et al. 5´-triphosphate RNA is the ligand for RIG-I. Science314(5801), 994–997 (2006).
   PubMed Web of Science ®Google Scholar
• Pichlmair A, Schulz O, Tan CP et al. RIG-I-mediated antiviral responses to single-stranded RNA bearing 5´-phosphates. Science314(5801), 997–1001 (2006).
   PubMed Web of Science ®Google Scholar
• Janeway CA Jr, Medzhitov R. Innate immune recognition. Annu. Rev. Immunol.20, 197–216 (2002).
   PubMed Web of Science ®Google Scholar
• Foti M, Granucci F, Pelizzola M, Beretta O, Ricciardi-Castagnoli P. Dendritic cells in pathogen recognition and induction of immune responses: a functional genomics approach. J. Leukoc. Biol.79(5), 913–916 (2006).
   PubMed Web of Science ®Google Scholar
• Shortman K, Naik SH. Steady-state and inflammatory dendritic-cell development. Nat. Rev. Immunol.7(1), 19–30 (2007).
   PubMed Web of Science ®Google Scholar
• Bell D, Young JW, Banchereau J. Dendritic cells. Adv. Immunol.72, 255–324 (1999).
   PubMed Web of Science ®Google Scholar
• Vremec D, Pooley J, Hochrein H, Wu L, Shortman K. CD4 and CD8 expression by dendritic cell subtypes in mouse thymus and spleen. J. Immunol.164(6), 2978–2986 (2000).
   PubMed Web of Science ®Google Scholar
• Heath WR, Belz GT, Behrens GM et al. Cross-presentation, dendritic cell subsets, and the generation of immunity to cellular antigens. Immunol. Rev.199, 9–26 (2004).
   PubMed Web of Science ®Google Scholar
• Yewdell JW, Haeryfar SM. Understanding presentation of viral antigens to CD8+ T cells in vivo: the key to rational vaccine design. Annu. Rev. Immunol.23, 651–682 (2005).
   PubMed Web of Science ®Google Scholar
• Liu YJ. IPC: professional type 1 interferon-producing cells and plasmacytoid dendritic cell precursors. Annu. Rev. Immunol.23, 275–306 (2005).
   PubMed Web of Science ®Google Scholar
• Katze MG, He Y, Gale M Jr. Viruses and interferon: a fight for supremacy. Nat. Rev. Immunol.2(9), 675–687 (2002).
   PubMed Web of Science ®Google Scholar
• Biron CA, Nguyen KB, Pien GC, Cousens LP, Salazar-Mather TP. Natural killer cells in antiviral defense: function and regulation by innate cytokines. Annu. Rev. Immunol.17, 189–220 (1999).
   PubMed Web of Science ®Google Scholar
• Le Bon A, Durand V, Kamphuis E et al. Direct stimulation of T cells by type I IFN enhances the CD8+ T cell response during cross-priming. J. Immunol.176(8), 4682–4689 (2006).
   PubMed Web of Science ®Google Scholar
• Gavin AL, Hoebe K, Duong B et al. Adjuvant-enhanced antibody responses in the absence of Toll-like receptor signaling. Science314(5807), 1936–1938 (2006).
   PubMed Web of Science ®Google Scholar
• Pulendran B. Division of labor and cooperation between dendritic cells. Nat. Immunol.7(7), 699–700 (2006).
   PubMed Web of Science ®Google Scholar
• Schlecht G, Garcia S, Escriou N, Freitas AA, Leclerc C, Dadaglio G. Murine plasmacytoid dendritic cells induce effector/memory CD8+ T-cell responses in vivo after viral stimulation. Blood104(6), 1808–1815 (2004).
   PubMedGoogle Scholar
• Krug A, Veeraswamy R, Pekosz A et al. Interferon-producing cells fail to induce proliferation of naive T cells but can promote expansion and T helper 1 differentiation of antigen-experienced unpolarized T cells. J. Exp. Med.197(7), 899–906 (2003).
   PubMed Web of Science ®Google Scholar
• Reis e Sousa C. Activation of dendritic cells: translating innate into adaptive immunity. Curr. Opin. Immunol.16(1), 21–25 (2004).
   PubMed Web of Science ®Google Scholar
• Lund JM, Linehan MM, Iijima N, Iwasaki A. Cutting edge: plasmacytoid dendritic cells provide innate immune protection against mucosal viral infection in situ. J. Immunol.177(11), 7510–7514 (2006).
   PubMedGoogle Scholar
• Allan RS, Smith CM, Belz GT et al. Epidermal viral immunity induced by CD8α+ dendritic cells but not by Langerhans cells. Science301(5641), 1925–1928 (2003).
   PubMed Web of Science ®Google Scholar
• Allan RS, Waithman J, Bedoui S et al. Migratory dendritic cells transfer antigen to a lymph node-resident dendritic cell population for efficient CTL priming. Immunity25(1), 153–162 (2006).
   PubMed Web of Science ®Google Scholar
• Williams MA, Bevan MJ. Effector and memory CTL differentiation. Annu. Rev. Immunol.25, 171–192 (2007).
   PubMed Web of Science ®Google Scholar
• Mescher MF, Curtsinger JM, Agarwal P et al. Signals required for programming effector and memory development by CD8+ T cells. Immunol. Rev.211, 81–92 (2006).
   PubMed Web of Science ®Google Scholar
• Chang JT, Palanivel VR, Kinjyo I et al. Asymmetric T lymphocyte division in the initiation of adaptive immune responses. Science315(5819), 1687–1691 (2007).
   PubMed Web of Science ®Google Scholar
• Romagnani S. Regulation of the T cell response. Clin. Exp. Allergy36(11), 1357–1366 (2006).
   PubMed Web of Science ®Google Scholar
• Pulendran B, Ahmed R. Translating innate immunity into immunological memory: implications for vaccine development. Cell124(4), 849–863 (2006).
   PubMed Web of Science ®Google Scholar
• Kaech SM, Ahmed R. Memory CD8+ T cell differentiation: initial antigen encounter triggers a developmental program in naive cells. Nat. Immunol.2(5), 415–422 (2001).
   PubMed Web of Science ®Google Scholar
• van Stipdonk MJ, Lemmens EE, Schoenberger SP. Naive CTLs require a single brief period of antigenic stimulation for clonal expansion and differentiation. Nat. Immunol.2(5), 423–429 (2001).
   PubMed Web of Science ®Google Scholar
• Bevan MJ, Fink PJ. The CD8 response on autopilot. Nat. Immunol.2(5), 381–382 (2001).
   PubMedGoogle Scholar
• Wherry EJ, Barber DL, Kaech SM, Blattman JN, Ahmed R. Antigen-independent memory CD8 T cells do not develop during chronic viral infection. Proc. Natl Acad. Sci. USA101(45), 16004–16009 (2004).
   PubMed Web of Science ®Google Scholar
• Bajenoff M, Wurtz O, Guerder S. Repeated antigen exposure is necessary for the differentiation, but not the initial proliferation, of naive CD4(+) T cells. J. Immunol.168(4), 1723–1729 (2002).
   PubMedGoogle Scholar
• Obst R, van Santen HM, Mathis D, Benoist C. Antigen persistence is required throughout the expansion phase of a CD4(+) T cell response. J. Exp. Med.201(10), 1555–1565 (2005).
   PubMedGoogle Scholar
• Shrikant P, Khoruts A, Mescher MF. CTLA-4 blockade reverses CD8+ T cell tolerance to tumor by a CD4+ T cell- and IL-2-dependent mechanism. Immunity11(4), 483–493 (1999).
   PubMed Web of Science ®Google Scholar
• Quezada SA, Jarvinen LZ, Lind EF, Noelle RJ. CD40/CD154 interactions at the interface of tolerance and immunity. Annu. Rev. Immunol.22, 307–328 (2004).
   PubMed Web of Science ®Google Scholar
• Janssen EM, Lemmens EE, Wolfe T, Christen U, von Herrath MG, Schoenberger SP. CD4+ T cells are required for secondary expansion and memory in CD8+ T lymphocytes. Nature421(6925), 852–856 (2003).
   PubMed Web of Science ®Google Scholar
• Sun JC, Williams MA, Bevan MJ. CD4+ T cells are required for the maintenance, not programming, of memory CD8+ T cells after acute infection. Nat. Immunol.5(9), 927–933 (2004).
   PubMed Web of Science ®Google Scholar
• Snapper CM, Paul WE. Interferon-γ and B cell stimulatory factor-1 reciprocally regulate Ig isotype production. Science236(4804), 944–947 (1987).
   PubMed Web of Science ®Google Scholar
• Cazac BB, Roes J. TGF-β receptor controls B cell responsiveness and induction of IgA in vivo. Immunity13(4), 443–451 (2000).
   PubMed Web of Science ®Google Scholar
• Coffman RL, Lebman DA, Shrader B. Transforming growth factor β specifically enhances IgA production by lipopolysaccharide-stimulated murine B lymphocytes. J. Exp. Med.170(3), 1039–1044 (1989).
   PubMed Web of Science ®Google Scholar
• Sonoda E, Matsumoto R, Hitoshi Y et al. Transforming growth factor β induces IgA production and acts additively with interleukin 5 for IgA production. J. Exp. Med.170(4), 1415–1420 (1989).
   PubMed Web of Science ®Google Scholar
• Schittek B, Rajewsky K. Maintenance of B-cell memory by long-lived cells generated from proliferating precursors. Nature346(6286), 749–751 (1990).
   PubMed Web of Science ®Google Scholar
• Maruyama M, Lam KP, Rajewsky K. Memory B-cell persistence is independent of persisting immunizing antigen. Nature407(6804), 636–642 (2000).
   PubMed Web of Science ®Google Scholar
• McHeyzer-Williams LJ, McHeyzer-Williams MG. Antigen-specific memory B cell development. Annu. Rev. Immunol.23, 487–513 (2005).
   PubMed Web of Science ®Google Scholar
• Kleindienst P, Brocker T. Concerted antigen presentation by dendritic cells and B cells is necessary for optimal CD4 T-cell immunity in vivo. Immunology115(4), 556–564 (2005).
   PubMedGoogle Scholar
• Dooms H, Abbas AK. Control of CD4+ T-cell memory by cytokines and costimulators. Immunol. Rev.211, 23–38 (2006).
   PubMed Web of Science ®Google Scholar
• Rogers PR, Song J, Gramaglia I, Killeen N, Croft M. OX40 promotes Bcl-xL and Bcl-2 expression and is essential for long-term survival of CD4 T cells. Immunity15(3), 445–455 (2001).
   PubMed Web of Science ®Google Scholar
• Ramon G. Sur l’augmentation anormale de l’antitoxine chez leschevaux producteurs de serum antidiphterique. Bull. Soc. Centr. Med. Vet.101, 227–234 (1925).
   Google Scholar
• Kumar S, Jones TR, Oakley MS et al. CpG oligodeoxynucleotide and Montanide ISA 51 adjuvant combination enhanced the protective efficacy of a subunit malaria vaccine. Infect. Immun.72(2), 949–957 (2004).
   PubMed Web of Science ®Google Scholar
• Cooper CL, Davis HL, Morris ML et al. CPG 7909, an immunostimulatory TLR9 agonist oligodeoxynucleotide, as adjuvant to Engerix-B HBV vaccine in healthy adults: a double-blind Phase I/II study. J. Clin. Immunol.24(6), 693–701 (2004).
   PubMed Web of Science ®Google Scholar
• Storni T, Ruedl C, Schwarz K, Schwendener RA, Renner WA, Bachmann MF. Nonmethylated CG motifs packaged into virus-like particles induce protective cytotoxic T cell responses in the absence of systemic side effects. J. Immunol.172(3), 1777–1785 (2004).
   PubMed Web of Science ®Google Scholar
• Boland G, Beran J, Lievens M et al. Safety and immunogenicity profile of an experimental hepatitis B vaccine adjuvanted with AS04. Vaccine23(3), 316–320 (2004).
   PubMed Web of Science ®Google Scholar
• Skeiky YA, Alderson MR, Ovendale PJ et al. Differential immune responses and protective efficacy induced by components of a tuberculosis polyprotein vaccine, Mtb72F, delivered as naked DNA or recombinant protein. J. Immunol.172(12), 7618–7628 (2004).
   PubMed Web of Science ®Google Scholar
• Schellack C, Prinz K, Egyed A et al. IC31, a novel adjuvant signaling via TLR9, induces potent cellular and humoral immune responses. Vaccine24(26), 5461–5472 (2006).
   PubMed Web of Science ®Google Scholar
• Agger EM, Rosenkrands I, Olsen AW et al. Protective immunity to tuberculosis with Ag85B-ESAT-6 in a synthetic cationic adjuvant system IC31. Vaccine24(26), 5452–5460 (2006).
   PubMed Web of Science ®Google Scholar
• Eickhoff TC, Myers M. Workshop summary. Aluminum in vaccines. Vaccine20(Suppl. 3), S1–S4 (2002).
   PubMed Web of Science ®Google Scholar
• Lindblad EB. Aluminium adjuvants – in retrospect and prospect. Vaccine22(27–28), 3658–3668 (2004).
   PubMed Web of Science ®Google Scholar
• HogenEsch H. Mechanisms of stimulation of the immune response by aluminum adjuvants. Vaccine20(Suppl. 3), S34–S39 (2002).
   PubMed Web of Science ®Google Scholar
• Brewer JM. (How) do aluminium adjuvants work? Immunol. Lett.102(1), 10–15 (2006).
   PubMed Web of Science ®Google Scholar
• Gupta RK, Chang AC, Griffin P, Rivera R, Siber GR. In vivo distribution of radioactivity in mice after injection of biodegradable polymer microspheres containing 14C-labeled tetanus toxoid. Vaccine14(15), 1412–1416 (1996).
   PubMed Web of Science ®Google Scholar
• Gallucci S, Lolkema M, Matzinger P. Natural adjuvants: endogenous activators of dendritic cells. Nat. Med.5(11), 1249–1255 (1999).
   PubMed Web of Science ®Google Scholar
• Near KA, Stowers AW, Jankovic D, Kaslow DC. Improved immunogenicity and efficacy of the recombinant 19-kilodalton merozoite surface protein 1 by the addition of oligodeoxynucleotide and aluminum hydroxide gel in a murine malaria vaccine model. Infect. Immun.70(2), 692–701 (2002).
   PubMedGoogle Scholar
• Xiao Y, Aldaz-Carroll L, Ortiz AM et al. A protein-based smallpox vaccine protects mice from vaccinia and ectromelia virus challenges when given as a prime and single boost. Vaccine25(7), 1214–1224 (2007).
   PubMed Web of Science ®Google Scholar
• Weeratna R, Comanita L, Davis HL. CPG ODN allows lower dose of antigen against hepatitis B surface antigen in BALB/c mice. Immunol. Cell Biol.81(1), 59–62 (2003).
   PubMed Web of Science ®Google Scholar
• Alderson MR, McGowan P, Baldridge JR, Probst P. TLR4 agonists as immunomodulatory agents. J. Endotoxin Res.12(5), 313–319 (2006).
   PubMedGoogle Scholar
• Nevens F, Zuckerman JN, Burroughs AK et al. Immunogenicity and safety of an experimental adjuvanted hepatitis B candidate vaccine in liver transplant patients. Liver Transpl.12(10), 1489–1495 (2006).
   PubMed Web of Science ®Google Scholar
• Hasan MS, Agosti JM, Reynolds KK , Tanzman E, Treanor JJ, Evans TG. Granulocyte macrophage colony-stimulating factor as an adjuvant for hepatitis B vaccination of healthy adults. J. Infect. Dis.180(6), 2023–2026 (1999).
   PubMed Web of Science ®Google Scholar
• Evans TG, Hasan M, Galibert L, Caron D. The use of Flt3 ligand as an adjuvant for hepatitis B vaccination of healthy adults. Vaccine21(3–4), 322–329 (2002).
   PubMed Web of Science ®Google Scholar
• Giannini SL, Hanon E, Moris P et al. Enhanced humoral and memory B cellular immunity using HPV16/18 L1 VLP vaccine formulated with the MPL/aluminium salt combination (AS04) compared to aluminium salt only. Vaccine24(33–34), 5937–5949 (2006).
   PubMed Web of Science ®Google Scholar
• Frazer I. God’s gift to women: the human papillomavirus vaccine. Immunity25(2), 179–184 (2006).
   PubMedGoogle Scholar
• Stanberry LR, Spruance SL, Cunningham AL et al. Glycoprotein-D-adjuvant vaccine to prevent genital herpes. N. Engl. J. Med.347(21), 1652–1661 (2002).
   PubMed Web of Science ®Google Scholar
• Moschos SA, Bramwell VW, Somavarapu S, Alpar HO. Modulating the adjuvanticity of alum by co-administration of muramyl di-peptide (MDP) or Quil-A. Vaccine24(8), 1081–1086 (2006).
   PubMed Web of Science ®Google Scholar
• Edell D, Bruce E, Hale K, Khoshoo V. Reduced long-term respiratory morbidity after treatment of respiratory syncytial virus bronchiolitis with ribavirin in previously healthy infants: a preliminary report. Pediatr. Pulmonol.25(3), 154–158 (1998).
   PubMed Web of Science ®Google Scholar
• Puri N, Sinko PJ. Adjuvancy enhancement of muramyl dipeptide by modulating its release from a physicochemically modified matrix of ovalbumin microspheres. II. In vivo investigation. J. Control Release69(1), 69–80 (2000).
   PubMed Web of Science ®Google Scholar
• Inohara N, Nunez G. NODs: intracellular proteins involved in inflammation and apoptosis. Nat. Rev. Immunol.3(5), 371–382 (2003).
   PubMed Web of Science ®Google Scholar
• Car BD, Eng VM, Lipman JM, Anderson TD. The toxicology of interleukin-12: a review. Toxicol. Pathol.27(1), 58–63 (1999).
   PubMed Web of Science ®Google Scholar
• Salem ML, Gillanders WE, Kadima AN et al. Review: novel nonviral delivery approaches for interleukin-12 protein and gene systems: curbing toxicity and enhancing adjuvant activity. J. Interferon Cytokine Res.26(9), 593–608 (2006).
   PubMed Web of Science ®Google Scholar
• Jankovic D, Caspar P, Zweig M et al. Adsorption to aluminum hydroxide promotes the activity of IL-12 as an adjuvant for antibody as well as type 1 cytokine responses to HIV-1 gp120. J. Immunol.159(5), 2409–2417 (1997).
   PubMed Web of Science ®Google Scholar
• Wang S, Liu X, Caulfield MJ. Adjuvant synergy in the response to hepatitis B vaccines. Vaccine21(27–30), 4297–4306 (2003).
   PubMed Web of Science ®Google Scholar
• O’Hagan DT, Rappuoli R. Novel approaches to vaccine delivery. Pharm. Res.21(9), 1519–1530 (2004).
   PubMed Web of Science ®Google Scholar
• Granoff DM, McHugh YE, Raff HV, Mokatrin AS, Van Nest GA. MF59 adjuvant enhances antibody responses of infant baboons immunized with Haemophilus influenzae type b and Neisseria meningitidis group C oligosaccharide-CRM197 conjugate vaccine. Infect. Immun.65(5), 1710–1715 (1997).
   PubMed Web of Science ®Google Scholar
• Podda A, Del Giudice G. MF59-adjuvanted vaccines: increased immunogenicity with an optimal safety profile. Expert Rev. Vaccines2(2), 197–203 (2003).
   PubMedGoogle Scholar
• Aucouturier J, Dupuis L, Deville S, Ascarateil S, Ganne V. Montanide ISA 720 and 51: a new generation of water in oil emulsions as adjuvants for human vaccines. Expert Rev. Vaccines1(1), 111–118 (2002).
   PubMed Web of Science ®Google Scholar
• Dupuis M, McDonald DM, Ott G. Distribution of adjuvant MF59 and antigen gD2 after intramuscular injection in mice. Vaccine18(5–6), 434–439 (1999).
   PubMed Web of Science ®Google Scholar
• Dupuis M, Murphy TJ, Higgins D et al. Dendritic cells internalize vaccine adjuvant after intramuscular injection. Cell Immunol.186(1), 18–27 (1998).
   PubMed Web of Science ®Google Scholar
• Vajdy M, Selby M, Medina-Selby A et al. Hepatitis C virus polyprotein vaccine formulations capable of inducing broad antibody and cellular immune responses. J. Gen. Virol.87(Pt 8), 2253–2262 (2006).
   PubMed Web of Science ®Google Scholar
• O’Hagan DT, Singh M, Kazzaz J et al. Synergistic adjuvant activity of immunostimulatory DNA and oil/water emulsions for immunization with HIV p55 gag antigen. Vaccine20(27–28), 3389–3398 (2002).
   PubMed Web of Science ®Google Scholar
• Graham BS, Keefer MC, McElrath MJ et al. Safety and immunogenicity of a candidate HIV-1 vaccine in healthy adults: recombinant glycoprotein (rgp) 120. A randomized, double-blind trial. NIAID AIDS Vaccine Evaluation Group. Ann. Intern. Med.125(4), 270–279 (1996).
   PubMedGoogle Scholar
• Ahlers JD, Belyakov IM, Terabe M et al. A push–pull approach to maximize vaccine efficacy: abrogating suppression with an IL-13 inhibitor while augmenting help with granulocyte/macrophage colony-stimulating factor and CD40L. Proc. Natl Acad. Sci. USA99(20), 13020–13025 (2002).
   PubMedGoogle Scholar
• Jeamwattanalert P, Mahakunkijcharoen Y, Kittigul L, Mahannop P, Pichyangkul S, Hirunpetcharat C. Long-lasting protective immune response to the 19-kilodalton carboxy-terminal fragment of plasmodium yoelii merozoite surface protein 1 in mice. Clin. Vaccine Immunol.14(4), 342–347 (2007).
   PubMedGoogle Scholar
• Roohvand F, Aghasadeghi MR, Sadat SM, Budkowska A, Khabiri AR. HCV core protein immunization with Montanide/CpG elicits strong Th1/Th2 and long-lived CTL responses. Biochem. Biophys. Res. Commun.354(3), 641–649 (2007).
   PubMedGoogle Scholar
• Ahlers JD, Belyakov IM, Matsui S, Berzofsky JA. Signals delivered through TCR instruct IL-12 receptor (IL-12R) expression: IL-12 and tumor necrosis factor-α synergize for IL-12R expression at low antigen dose. Int. Immunol.13(11), 1433–1442 (2001).
   PubMed Web of Science ®Google Scholar
• Skene CD, Sutton P. Saponin-adjuvanted particulate vaccines for clinical use. Methods40(1), 53–59 (2006).
   PubMed Web of Science ®Google Scholar
• Garcon N, Heppner DG, Cohen J. Development of RTS,S/AS02: a purified subunit-based malaria vaccine candidate formulated with a novel adjuvant. Expert Rev. Vaccines2(2), 231–238 (2003).
   PubMedGoogle Scholar
• Newman MJ, Wu JY, Gardner BH et al. Induction of cross-reactive cytotoxic T-lymphocyte responses specific for HIV-1 gp120 using saponin adjuvant (QS-21) supplemented subunit vaccine formulations. Vaccine15(9), 1001–1007 (1997).
   PubMed Web of Science ®Google Scholar
• Kim YJ, Wang P, Navarro-Villalobos M, Rohde BD, Derryberry J, Gin DY. Synthetic studies of complex immunostimulants from Quillaja saponaria: synthesis of the potent clinical immunoadjuvant QS-21Aapi. J. Am. Chem. Soc.128(36), 11906–11915 (2006).
   PubMed Web of Science ®Google Scholar
• Macete E, Aponte JJ, Guinovart C et al. Safety and immunogenicity of the RTS,S/AS02A candidate malaria vaccine in children aged 1–4 in Mozambique. Trop. Med. Int. Health12(1), 37–46 (2007).
   PubMed Web of Science ®Google Scholar
• Stewart VA, McGrath SM, Walsh DS et al. Pre-clinical evaluation of new adjuvant formulations to improve the immunogenicity of the malaria vaccine RTS,S/AS02A. Vaccine24(42–43), 6483–6492 (2006).
   PubMed Web of Science ®Google Scholar
• Ha SJ, Park SH, Kim HJ et al. Enhanced immunogenicity and protective efficacy with the use of interleukin-12-encapsulated microspheres plus AS01B in tuberculosis subunit vaccination. Infect. Immun.74(8), 4954–4959 (2006).
   PubMed Web of Science ®Google Scholar
• Sanders MT, Brown LE, Deliyannis G, Pearse MJ. ISCOM-based vaccines: the second decade. Immunol. Cell Biol.83(2), 119–128 (2005).
   PubMed Web of Science ®Google Scholar
• Andersen CS, Dietrich J, Agger EM, Lycke NY, Lovgren K, Andersen P. The combined CTA1-DD/ISCOMs vector is an effective intranasal adjuvant for boosting prior Mycobacterium bovis BCG immunity to Mycobacterium tuberculosis. Infect. Immun.75(1), 408–416 (2007).
   PubMed Web of Science ®Google Scholar
• Boyle J, Eastman D, Millar C et al. The utility of ISCOMATRIX™ adjuvant for dose reduction of antigen for vaccines requiring antibody responses. Vaccine25(14), 2541–2544 (2007).
   PubMed Web of Science ®Google Scholar
• Smith RE, Donachie AM, Grdic D, Lycke N, Mowat AM. Immune-stimulating complexes induce an IL-12-dependent cascade of innate immune responses. J. Immunol.162(9), 5536–5546 (1999).
   PubMed Web of Science ®Google Scholar
• Robson NC, Beacock-Sharp H, Donachie AM, Mowat AM. Dendritic cell maturation enhances CD8+ T-cell responses to exogenous antigen via a proteasome-independent mechanism of major histocompatibility complex class I loading. Immunology109(3), 374–383 (2003).
   PubMed Web of Science ®Google Scholar
• Windon RG, Chaplin PJ, Beezum L et al. Induction of lymphocyte recruitment in the absence of a detectable immune response. Vaccine19(4–5), 572–578 (2000).
   PubMed Web of Science ®Google Scholar
• Warger T, Osterloh P, Rechtsteiner G et al. Synergistic activation of dendritic cells by combined Toll-like receptor ligation induces superior CTL responses in vivo. Blood108(2), 544–550 (2006).
   PubMed Web of Science ®Google Scholar
• Ahonen CL, Doxsee CL, McGurran SM et al. Combined TLR and CD40 triggering induces potent CD8+ T cell expansion with variable dependence on type I IFN. J. Exp. Med.199(6), 775–784 (2004).
   PubMed Web of Science ®Google Scholar
• Chavan R, Marfatia KA, An IC, Garber DA, Feinberg MB. Expression of CCL20 and granulocyte-macrophage colony-stimulating factor, but not Flt3-L, from modified vaccinia virus ankara enhances antiviral cellular and humoral immune responses. J. Virol.80(15), 7676–7687 (2006).
   PubMed Web of Science ®Google Scholar
• Ahlers JD, Belyakov IM, Matsui S, Berzofsky JA. Mechanisms of cytokine synergy essential for vaccine protection against viral challenge. Int. Immunol.13(7), 897–908 (2001).
   PubMed Web of Science ®Google Scholar
• Jiang W, Baker HJ, Smith BF. Mucosal immunization with helicobacter, CpG DNA, and cholera toxin is protective. Infect. Immun.71(1), 40–46 (2003).
   PubMed Web of Science ®Google Scholar
• Berry LJ, Hickey DK, Skelding KA et al. Transcutaneous immunization with combined cholera toxin and CpG adjuvant protects against Chlamydia muridarum genital tract infection. Infect. Immun.72(2), 1019–1028 (2004).
   PubMed Web of Science ®Google Scholar
• Vajdy M. Generation and maintenance of mucosal memory B cell responses? Curr. Med. Chem.13(25), 3023–3037 (2006).
   PubMedGoogle Scholar
• Peppoloni S, Ruggiero P, Contorni M et al. Mutants of the Escherichia coli heat-labile enterotoxin as safe and strong adjuvants for intranasal delivery of vaccines. Expert Rev. Vaccines2(2), 285–293 (2003).
   PubMedGoogle Scholar
• Baudner BC, Balland O, Giuliani MM et al. Enhancement of protective efficacy following intranasal immunization with vaccine plus a nontoxic LTK63 mutant delivered with nanoparticles. Infect. Immun.70(9), 4785–4790 (2002).
   PubMed Web of Science ®Google Scholar
• Singh M, Briones M, O’Hagan DT. A novel bioadhesive intranasal delivery system for inactivated influenza vaccines. J. Control Release70(3), 267–276 (2001).
   PubMed Web of Science ®Google Scholar
• Kang SM, Yao Q, Guo L, Compans RW. Mucosal immunization with virus-like particles of simian immunodeficiency virus conjugated with cholera toxin subunit B. J. Virol.77(18), 9823–9830 (2003).
   PubMed Web of Science ®Google Scholar
• Agren L, Sverremark E, Ekman L et al. The ADP-ribosylating CTA1-DD adjuvant enhances T cell-dependent and independent responses by direct action on B cells involving anti-apoptotic Bcl-2- and germinal center-promoting effects. J. Immunol.164(12), 6276–6286 (2000).
   PubMed Web of Science ®Google Scholar
• Mowat AM, Donachie AM, Jagewall S et al. CTA1-DD-immune stimulating complexes: a novel, rationally designed combined mucosal vaccine adjuvant effective with nanogram doses of antigen. J. Immunol.167(6), 3398–3405 (2001).
   PubMed Web of Science ®Google Scholar
• Wiker HG, Mustafa T, Malen H, Riise AM. Vaccine approaches to prevent tuberculosis. Scand. J. Immunol.64(3), 243–250 (2006).
   PubMed Web of Science ®Google Scholar
• Skeiky YA, Sadoff JC. Advances in tuberculosis vaccine strategies. Nat. Rev. Microbiol.4(6), 469–476 (2006).
   PubMed Web of Science ®Google Scholar
• Staats HF, Bradney CP, Gwinn WM et al. Cytokine requirements for induction of systemic and mucosal CTL after nasal immunization. J. Immunol.167(9), 5386–5394 (2001).
   PubMed Web of Science ®Google Scholar
• Bradney CP, Sempowski GD, Liao HX, Haynes BF, Staats HF. Cytokines as adjuvants for the induction of anti-human immunodeficiency virus peptide immunoglobulin G (IgG) and IgA antibodies in serum and mucosal secretions after nasal immunization. J. Virol.76(2), 517–524 (2002).
   PubMed Web of Science ®Google Scholar
• Staats HF, Ennis FA Jr. IL-1 is an effective adjuvant for mucosal and systemic immune responses when coadministered with protein immunogens. J. Immunol.162(10), 6141–6147 (1999).
   PubMed Web of Science ®Google Scholar
• Moschos SA, Bramwell VW, Somavarapu S, Alpar HO. Comparative immunomodulatory properties of a chitosan-MDP adjuvant combination following intranasal or intramuscular immunisation. Vaccine23(16), 1923–1930 (2005).
   PubMed Web of Science ®Google Scholar
• van der Lubben IM, Verhoef JC, Borchard G, Junginger HE. Chitosan and its derivatives in mucosal drug and vaccine delivery. Eur. J. Pharm. Sci.14(3), 201–207 (2001).
   PubMed Web of Science ®Google Scholar
• Zaharoff DA, Rogers CJ, Hance KW, Schlom J, Greiner JW. Chitosan solution enhances both humoral and cell-mediated immune responses to subcutaneous vaccination. Vaccine25(11), 2085–2094 (2007).
   PubMed Web of Science ®Google Scholar
• Gurunathan S, Klinman DM, Seder RA. DNA vaccines: immunology application, and optimization. Annu. Rev. Immunol.18, 927–974 (2000).
   PubMed Web of Science ®Google Scholar
• Polack FP, Lee SH, Permar S et al. Successful DNA immunization against measles: neutralizing antibody against either the hemagglutinin or fusion glycoprotein protects rhesus macaques without evidence of atypical measles. Nat. Med.6(7), 776–781 (2000).
   PubMed Web of Science ®Google Scholar
• Barouch DH. Rational design of gene-based vaccines. J. Pathol.208(2), 283–289 (2006).
   PubMed Web of Science ®Google Scholar
• Corr M, Tighe H. Plasmid DNA vaccination: mechanism of antigen presentation. Springer Semin. Immunopathol.19(2), 139–145 (1997).
   PubMed Web of Science ®Google Scholar
• Sumida SM, McKay PF, Truitt DM et al. Recruitment and expansion of dendritic cells in vivo potentiate the immunogenicity of plasmid DNA vaccines. J. Clin. Invest.114(9), 1334–1342 (2004).
   PubMed Web of Science ®Google Scholar
• Encke J, Bernardin J, Geib J, Barbakadze G, Bujdoso R, Stremmel W. Genetic vaccination with Flt3-L and GM-CSF as adjuvants: Enhancement of cellular and humoral immune responses that results in protective immunity in a murine model of hepatitis C virus infection. World J. Gastroenterol.12(44), 7118–7125 (2006).
   PubMedGoogle Scholar
• Pulendran B, Banchereau J, Burkeholder S et al. Flt3-ligand and granulocyte colony-stimulating factor mobilize distinct human dendritic cell subsets in vivo. J. Immunol.165(1), 566–572 (2000).
   PubMed Web of Science ®Google Scholar
• Mwangi W, Brown WC, Lewin HA et al. DNA-encoded fetal liver tyrosine kinase 3 ligand and granulocyte macrophage-colony-stimulating factor increase dendritic cell recruitment to the inoculation site and enhance antigen-specific CD4+ T cell responses induced by DNA vaccination of outbred animals. J. Immunol.169(7), 3837–3846 (2002).
   PubMed Web of Science ®Google Scholar
• Iwasaki A, Stiernholm BJ, Chan AK, Berinstein NL, Barber BH. Enhanced CTL responses mediated by plasmid DNA immunogens encoding costimulatory molecules and cytokines. J. Immunol.158(10), 4591–4601 (1997).
   PubMed Web of Science ®Google Scholar
• Robinson HL, Montefiori DC, Villinger F et al. Studies on GM-CSF DNA as an adjuvant for neutralizing Ab elicited by a DNA/MVA immunodeficiency virus vaccine. Virology352(2), 285–294 (2006).
   PubMed Web of Science ®Google Scholar
• Ahlers JD, Belyakov IM, Berzofsky JA. Cytokine, chemokine, and costimulatory molecule modulation to enhance efficacy of HIV vaccines. Curr. Mol. Med.3(3), 285–301 (2003).
   PubMedGoogle Scholar
• Burger JA, Mendoza RB, Kipps TJ. Plasmids encoding granulocyte–macrophage colony-stimulating factor and CD154 enhance the immune response to genetic vaccines. Vaccine19(15–16), 2181–2189 (2001).
   PubMedGoogle Scholar
• Kennedy NJ, Spithill TW, Tennent J, Wood PR, Piedrafita D. DNA vaccines in sheep: CTLA-4 mediated targeting and CpG motifs enhance immunogenicity in a DNA prime/protein boost strategy. Vaccine24(7), 970–979 (2006).
   PubMedGoogle Scholar
• Ramshaw IA, Andrew ME, Phillips SM, Boyle DB, Coupar BE. Recovery of immunodeficient mice from a vaccinia virus/IL-2 recombinant infection. Nature329(6139), 545–546 (1987).
   PubMed Web of Science ®Google Scholar
• Dale CJ, De Rose R, Wilson KM et al. Evaluation in macaques of HIV-1 DNA vaccines containing primate CpG motifs and fowlpoxvirus vaccines co-expressing IFNγ or IL-12. Vaccine23(2), 188–197 (2004).
   PubMed Web of Science ®Google Scholar
• Bembridge GP, Lopez JA, Cook R, Melero JA, Taylor G. Recombinant vaccinia virus coexpressing the F protein of respiratory syncytial virus (RSV) and interleukin-4 (IL-4) does not inhibit the development of RSV-specific memory cytotoxic T lymphocytes, whereas priming is diminished in the presence of high levels of IL-2 or γ interferon. J. Virol.72(5), 4080–4087 (1998).
   PubMed Web of Science ®Google Scholar
• Konig P, Beer M, Makoschey B et al. Recombinant virus-expressed bovine cytokines do not improve efficacy of a bovine herpesvirus 1 marker vaccine strain. Vaccine22(2), 202–212 (2003).
   PubMed Web of Science ®Google Scholar
• Cooper DA, Workman C, Puls RL et al. Randomised, placebo-controlled, Phase1/2a evaluation of the safety, biological activity and antiretroviral properties of an avipox virus vaccine expressing HIV gag–pol and interferon-γ in HIV-1 infected subjects. In: 11th Annual Conference on the Retroviruses and Opportunistic Infections. CA, USA (2004).
   Google Scholar
• Emery S, Workman C, Puls RL et al. Randomized, placebo-controlled, Phase I/IIa evaluation of the safety and immunogenicity of fowlpox virus expressing HIV gag–pol and interferon-γ in HIV-1 infected subjects. Hum. Vaccin.1(6), 232–238 (2005).
   PubMed Web of Science ®Google Scholar
• Abaitua F, Rodriguez JR, Garzon A, Rodriguez D, Esteban M. Improving recombinant MVA immune responses: potentiation of the immune responses to HIV-1 with MVA and DNA vectors expressing Env and the cytokines IL-12 and IFN-γ. Virus Res.116(1–2), 11–20 (2006).
   PubMed Web of Science ®Google Scholar
• Oh S, Berzofsky JA, Burke DS, Waldmann TA, Perera LP. Coadministration of HIV vaccine vectors with vaccinia viruses expressing IL-15 but not IL-2 induces long-lasting cellular immunity. Proc. Natl Acad. Sci. USA100(6), 3392–3397 (2003).
   PubMed Web of Science ®Google Scholar
• Hovav AH, Fishman Y, Bercovier H. γ interferon and monophosphoryl lipid A- trehalose dicorynomycolate are efficient adjuvants for Mycobacterium tuberculosis multivalent acellular vaccine. Infect. Immun.73(1), 250–257 (2005).
   PubMedGoogle Scholar
• Bennekov T, Dietrich J, Rosenkrands I , Stryhn A, Doherty TM, Andersen P. Alteration of epitope recognition pattern in Ag85B and ESAT-6 has a profound influence on vaccine-induced protection against Mycobacterium tuberculosis. Eur. J. Immunol.36(12), 3346–3355 (2006).
   PubMed Web of Science ®Google Scholar
• Naito T, Kaneko Y, Kozbor D. Oral vaccination with modified vaccinia virus Ankara attached covalently to TMPEG-modified cationic liposomes overcomes pre-existing poxvirus immunity from recombinant vaccinia immunization. J. Gen. Virol.88(Pt 1), 61–70 (2007).
   PubMed Web of Science ®Google Scholar
• Grgacic EV, Anderson DA. Virus-like particles: passport to immune recognition. Methods40(1), 60–65 (2006).
   PubMed Web of Science ®Google Scholar
• Young KR, McBurney SP, Karkhanis LU, Ross TM. Virus-like particles: designing an effective AIDS vaccine. Methods40(1), 98–117 (2006).
   PubMed Web of Science ®Google Scholar
• Wagner R, Teeuwsen VJ, Deml L et al. Cytotoxic T cells and neutralizing antibodies induced in rhesus monkeys by virus-like particle HIV vaccines in the absence of protection from SHIV infection. Virology245(1), 65–74 (1998).
   PubMedGoogle Scholar
• O’Neill E, Martinez I, Villinger F et al. Protection by SIV VLP DNA prime/protein boost following mucosal SIV challenge is markedly enhanced by IL-12/GM-CSF co-administration. J. Med. Primatol.31(4–5), 217–227 (2002).
   PubMed Web of Science ®Google Scholar
• Oh YK, Sohn T, Park JS et al. Enhanced mucosal and systemic immunogenicity of human papillomavirus-like particles encapsidating interleukin-2 gene adjuvant. Virology328(2), 266–273 (2004).
   PubMedGoogle Scholar
• Toka FN, Gierynska M, Suvas S, Schoenberger SP, Rouse BT. Rescue of memory CD8+ T cell reactivity in peptide/TLR9 ligand immunization by codelivery of cytokines or CD40 ligation. Virology331(1), 151–158 (2005).
   PubMedGoogle Scholar
• Myers L, Lee SW, Rossi RJ et al. Combined CD137 (4–1BB) and adjuvant therapy generates a developing pool of peptide-specific CD8 memory T cells. Int. Immunol.18(2), 325–333 (2006).
   PubMed Web of Science ®Google Scholar
• Bolesta E, Kowalczyk A, Wierzbicki A et al. Increased level and longevity of protective immune responses induced by DNA vaccine expressing the HIV-1 Env glycoprotein when combined with IL-21 and IL-15 gene delivery. J. Immunol.177(1), 177–191 (2006).
   PubMed Web of Science ®Google Scholar
• Holm C, Nyvold CG, Paludan SR, Thomsen AR, Hokland M. Interleukin-21 mRNA expression during virus infections. Cytokine33(1), 41–45 (2006).
   PubMed Web of Science ®Google Scholar
• WHO. Meeting of the Immunization Strategic Advisory Group of Experts, November 2006 – conclusions and recommendations. Wkly Epidemiol. Rec.82(1–2), 1–16 (2007).
   PubMedGoogle Scholar
• Young D, Dye C. The development and impact of tuberculosis vaccines. Cell124(4), 683–687 (2006).
   PubMed Web of Science ®Google Scholar
• McMichael AJ. HIV vaccines. Annu. Rev. Immunol.24, 227–255 (2006).
   PubMed Web of Science ®Google Scholar
• Bembridge GP, Rodriguez N, Garcia-Beato R, Nicolson C, Melero JA, Taylor G. Respiratory syncytial virus infection of gene gun vaccinated mice induces Th2-driven pulmonary eosinophilia even in the absence of sensitisation to the fusion (F) or attachment (G) protein. Vaccine19(9–10), 1038–1046 (2000).
   PubMedGoogle Scholar
• Kornbluth RS, Stone GW. Immunostimulatory combinations: designing the next generation of vaccine adjuvants. J. Leukoc. Biol.80(5), 1084–1102 (2006).
   PubMedGoogle Scholar